ECSP24036299A - Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) - Google Patents
Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt)Info
- Publication number
- ECSP24036299A ECSP24036299A ECSENADI202436299A ECDI202436299A ECSP24036299A EC SP24036299 A ECSP24036299 A EC SP24036299A EC SENADI202436299 A ECSENADI202436299 A EC SENADI202436299A EC DI202436299 A ECDI202436299 A EC DI202436299A EC SP24036299 A ECSP24036299 A EC SP24036299A
- Authority
- EC
- Ecuador
- Prior art keywords
- agt
- compositions
- methods
- angiotensinogen
- protein expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130832 | 2021-11-16 | ||
| CN2022081578 | 2022-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP24036299A true ECSP24036299A (es) | 2024-07-31 |
Family
ID=86396260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202436299A ECSP24036299A (es) | 2021-11-16 | 2024-05-13 | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20240084304A1 (https=) |
| EP (1) | EP4435103A4 (https=) |
| JP (1) | JP7829035B2 (https=) |
| KR (1) | KR20240103025A9 (https=) |
| CN (1) | CN116940682A (https=) |
| AU (1) | AU2022394667A1 (https=) |
| CA (1) | CA3238865A1 (https=) |
| CL (1) | CL2024001429A1 (https=) |
| CO (1) | CO2024006020A2 (https=) |
| CR (1) | CR20240196A (https=) |
| DO (1) | DOP2024000083A (https=) |
| EC (1) | ECSP24036299A (https=) |
| IL (1) | IL312811A (https=) |
| JO (1) | JOP20240109A1 (https=) |
| MX (1) | MX2024005862A (https=) |
| PE (1) | PE20241933A1 (https=) |
| TW (1) | TW202334422A (https=) |
| WO (1) | WO2023088227A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| EP4562158A1 (en) | 2023-06-13 | 2025-06-04 | Arnatar Therapeutics, Inc | Advanced rna targeting (arnatar) for angiotensinogen |
| WO2025007961A1 (zh) * | 2023-07-06 | 2025-01-09 | 大睿生物 | 调控AGT表达的dsRNA分子 |
| TW202509216A (zh) * | 2023-07-14 | 2025-03-01 | 大陸商北京安龍生物醫藥有限公司 | 靶向血管收縮素原的寡核苷酸及其用途 |
| CN119585432B (zh) * | 2023-08-22 | 2025-08-12 | 成都先衍生物技术有限公司 | 一种靶向AGT基因表达的siRNA及其缀合物和用途 |
| WO2025130862A1 (zh) * | 2023-12-18 | 2025-06-26 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| CN120350001A (zh) * | 2024-01-22 | 2025-07-22 | 尧唐(上海)生物科技有限公司 | 靶向AGT基因的gRNA及其应用 |
| CN119040330B (zh) * | 2024-11-01 | 2025-03-04 | 北京悦康科创医药科技股份有限公司 | 一种调控AGT基因表达的siRNA及其用途 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP0906123A4 (en) * | 1996-03-15 | 1999-05-26 | Univ Florida | ANGIOTENSINOGEN mRNA SPECIFIC OLIGONUCLEOTIDES |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| EP1841464B1 (en) | 2005-01-24 | 2012-06-27 | Alnylam Pharmaceuticals Inc. | Rnai modulation of the nogo-l or nogo-r gene and uses thereof |
| KR20080068019A (ko) | 2005-09-15 | 2008-07-22 | 산타리스 팔마 에이/에스 | 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물 |
| CN101292034A (zh) | 2005-09-15 | 2008-10-22 | 桑塔里斯制药公司 | 抑制apo-b100表达的rna拮抗化合物 |
| WO2008137751A2 (en) | 2007-05-02 | 2008-11-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina) |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| US11414664B2 (en) | 2008-12-18 | 2022-08-16 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CN103555722B (zh) | 2009-04-03 | 2016-08-31 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
| US20110196141A1 (en) | 2009-09-07 | 2011-08-11 | Council Of Scientific & Industrial Research | Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides |
| TWI458493B (zh) | 2009-09-25 | 2014-11-01 | Iner Aec Executive Yuan | 新穎肝標靶藥劑與合成方法 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012145582A2 (en) | 2011-04-22 | 2012-10-26 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibitions of egfr by double-stranded rna |
| CN102260673A (zh) | 2011-07-12 | 2011-11-30 | 深圳职业技术学院 | 靶向人血管紧张素原的rna干扰片段、表达载体与应用 |
| SI3366775T2 (sl) | 2011-11-18 | 2025-12-31 | Alnylam Pharmaceuticals, Inc. | Modificirana sredstva RNAI |
| EP3822352A3 (en) | 2012-05-24 | 2021-11-03 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein(a) expression |
| WO2014018930A1 (en) * | 2012-07-27 | 2014-01-30 | Isis Pharmaceuticals. Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| TWI553017B (zh) | 2012-12-28 | 2016-10-11 | 行政院原子能委員會核能研究所 | 新穎膽道掃描用造影劑及其製造方法 |
| CN103103192A (zh) | 2013-01-18 | 2013-05-15 | 深圳职业技术学院 | 靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用 |
| CA2900238A1 (en) | 2013-02-22 | 2014-08-28 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| US9994846B2 (en) | 2013-10-25 | 2018-06-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
| EP3065783A4 (en) | 2013-11-06 | 2017-06-21 | Merck Sharp & Dohme Corp. | Dual molecular delivery of oligonucleotides and peptide containing conjugates |
| HUE052709T2 (hu) | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| AU2015264038B2 (en) | 2014-05-22 | 2021-02-11 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (AGT) iRNA compositions and methods of use thereof |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| CA2979703A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of factor xii |
| WO2016196111A1 (en) * | 2015-06-01 | 2016-12-08 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CN113817735A (zh) | 2015-10-08 | 2021-12-21 | Ionis制药公司 | 用于调节血管紧张素原表达的化合物和方法 |
| CA3020585A1 (en) | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
| CA3033867A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| US11504391B1 (en) | 2016-11-23 | 2022-11-22 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
| DK3607069T3 (da) | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
| EP3649243A1 (en) | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| KR20240161202A (ko) | 2017-09-11 | 2024-11-12 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
| HRP20230127T1 (hr) | 2017-11-13 | 2023-03-31 | Silence Therapeutics Gmbh | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici |
| IL276043B2 (en) | 2018-01-29 | 2024-06-01 | Hoffmann La Roche | Process for the preparation of galnac oligonucleotide conjugates |
| WO2019217397A2 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| PH12021550801B1 (en) | 2018-11-13 | 2024-04-26 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| WO2020123410A1 (en) | 2018-12-10 | 2020-06-18 | Amgen Inc. | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US20200385713A1 (en) | 2019-01-22 | 2020-12-10 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| EP3923989A1 (en) | 2019-03-21 | 2021-12-22 | Mitotherapeutix LLC | Multivalent ligand clusters for targeted delivery of therapeutic agents |
| WO2020236526A1 (en) | 2019-05-23 | 2020-11-26 | Stratos Genomics, Inc. | Translocation control elements, reporter codes, and further means for translocation control for use in nanopore sequencing |
| IL291251B1 (en) | 2019-09-10 | 2026-02-01 | Daiichi Sankyo Co Ltd | Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production |
| BR112022009216A2 (pt) | 2019-11-13 | 2022-08-02 | Alnylam Pharmaceuticals Inc | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) |
| MX2022007005A (es) | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
| PE20221578A1 (es) | 2020-03-06 | 2022-10-06 | Aligos Therapeutics Inc | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas |
| US11649458B2 (en) * | 2020-05-05 | 2023-05-16 | University Of Kentucky Research Foundation | Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| WO2022028457A1 (zh) | 2020-08-04 | 2022-02-10 | 上海拓界生物医药科技有限公司 | 抑制凝血因子XI表达的siRNA、组合物及其医药用途 |
| US12435336B2 (en) | 2020-08-05 | 2025-10-07 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting LPA expression |
| WO2022079221A1 (en) | 2020-10-16 | 2022-04-21 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| CN114763547A (zh) | 2021-01-14 | 2022-07-19 | 施能康生物科技有限公司 | 靶向血管紧张素原的核酸及其用途 |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| EP4176061A1 (en) | 2021-01-30 | 2023-05-10 | E-Therapeutics plc | Nucleic acids containing abasic nucleotides |
| WO2022232650A1 (en) | 2021-04-30 | 2022-11-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing agt expression |
| AU2022303164A1 (en) | 2021-06-30 | 2024-01-18 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
| EP4381071A1 (en) * | 2021-08-04 | 2024-06-12 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing angiotensinogen (agt) |
| WO2023041508A2 (en) | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041079A1 (zh) | 2021-09-18 | 2023-03-23 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| US20240401045A1 (en) | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| CN120775847A (zh) | 2021-10-20 | 2025-10-14 | 厦门甘宝利生物医药有限公司 | Agt抑制剂及其用途 |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| TW202345865A (zh) | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| US20240041913A1 (en) * | 2022-04-01 | 2024-02-08 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| KR20250046303A (ko) * | 2022-08-05 | 2025-04-02 | 사네진 바이오 유에스에이 인크. | 안지오텐시노겐 (agt)을 표적화하는 이중 가닥 rna 및 그의 사용 방법 |
| TW202430193A (zh) | 2022-12-20 | 2024-08-01 | 美商靖因藥業（上海）有限公司 | 靶向agt之聚核酸分子及其用途 |
| WO2024187193A2 (en) | 2023-03-09 | 2024-09-12 | Basecure Therapeutics Llc | Compositions and methods for inhibition of expression of angiotensinogen (agt) genes |
-
2022
- 2022-11-15 IL IL312811A patent/IL312811A/en unknown
- 2022-11-15 PE PE2024001073A patent/PE20241933A1/es unknown
- 2022-11-15 MX MX2024005862A patent/MX2024005862A/es unknown
- 2022-11-15 WO PCT/CN2022/131861 patent/WO2023088227A1/zh not_active Ceased
- 2022-11-15 CN CN202280019061.5A patent/CN116940682A/zh active Pending
- 2022-11-15 CR CR20240196A patent/CR20240196A/es unknown
- 2022-11-15 CA CA3238865A patent/CA3238865A1/en active Pending
- 2022-11-15 AU AU2022394667A patent/AU2022394667A1/en active Pending
- 2022-11-15 EP EP22894761.0A patent/EP4435103A4/en active Pending
- 2022-11-15 KR KR1020247019545A patent/KR20240103025A9/ko active Pending
- 2022-11-15 JP JP2024528580A patent/JP7829035B2/ja active Active
- 2022-11-16 TW TW111143719A patent/TW202334422A/zh unknown
-
2023
- 2023-09-25 US US18/473,829 patent/US20240084304A1/en active Pending
-
2024
- 2024-05-10 CO CONC2024/0006020A patent/CO2024006020A2/es unknown
- 2024-05-13 EC ECSENADI202436299A patent/ECSP24036299A/es unknown
- 2024-05-13 CL CL2024001429A patent/CL2024001429A1/es unknown
- 2024-05-13 DO DO2024000083A patent/DOP2024000083A/es unknown
- 2024-05-14 JO JOJO/P/2024/0109A patent/JOP20240109A1/ar unknown
-
2025
- 2025-03-19 US US19/084,507 patent/US12534726B2/en active Active
- 2025-12-12 US US19/418,791 patent/US20260103705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL312811A (en) | 2024-07-01 |
| KR20240103025A9 (ko) | 2025-12-10 |
| CN116940682A (zh) | 2023-10-24 |
| TW202334422A (zh) | 2023-09-01 |
| CR20240196A (es) | 2024-07-08 |
| EP4435103A4 (en) | 2025-11-26 |
| US20260103705A1 (en) | 2026-04-16 |
| PE20241933A1 (es) | 2024-09-24 |
| US12534726B2 (en) | 2026-01-27 |
| KR20240103025A (ko) | 2024-07-03 |
| CL2024001429A1 (es) | 2024-11-08 |
| DOP2024000083A (es) | 2024-08-15 |
| JOP20240109A1 (ar) | 2024-05-14 |
| CO2024006020A2 (es) | 2024-08-08 |
| AU2022394667A1 (en) | 2024-06-13 |
| JP2024543496A (ja) | 2024-11-21 |
| WO2023088227A1 (zh) | 2023-05-25 |
| CA3238865A1 (en) | 2023-05-25 |
| JP7829035B2 (ja) | 2026-03-12 |
| US20250215429A1 (en) | 2025-07-03 |
| MX2024005862A (es) | 2024-07-10 |
| EP4435103A1 (en) | 2024-09-25 |
| US20240084304A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000083A (es) | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) | |
| CL2023002870A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso | |
| DOP2024000141A (es) | Composición y método para inhibir la expresión de proteína lpa(apo(a)) | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CL2022001256A1 (es) | Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt | |
| CO2020009861A2 (es) | Inhibidores pd-1/pd-l1 | |
| PE20110358A1 (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias | |
| MX2025007610A (es) | Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas | |
| MX2020013357A (es) | Polimerasas, composiciones y metodos de uso. | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| CO2022012196A2 (es) | Composiciones y métodos para la edición de genes de calicreína (klkb1) | |
| MX2021013913A (es) | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. | |
| CO2024006046A2 (es) | Composiciones de arni contra el factor b del complemento (cfb) y sus métodos de uso | |
| MX2024004195A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2025015672A (es) | Composiciones y metodos para inhibir la expresion del factor del complemento b (cfb) | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| MX2024005818A (es) | Arnip dirigido al angiotensinogeno y uso farmaceutico del mismo. | |
| CO2025017101A2 (es) | Composiciones y métodos para inhibir la expresión del factor de coagulación xi (fxi) | |
| CO2021015130A2 (es) | Péptidos bnip3 para el tratamiento de la lesión por reperfusión | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2016010719A (es) | Ensayos de aclaramiento de sustratos para enzimas lisosomales. | |
| RU2014145910A (ru) | Способы воздействия на экспрессию гена APOE | |
| RU2014144701A (ru) | Способы воздействия на экспрессию гена TER1 |